GeNeuro SA

MEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Jesús Martin-Garcia, founder and CEO of Geneva-based GeNeuro SA , is a man on a mission. He has been forging a clinical path for what would become the monoclonal antibody temelimab (previously known

The Novo Nordisk Foundation and the Broad Institute introduced a new Center for Genomic Mechanisms of Disease research unit on 15 September, to be housed at the Harvard University / Massachusetts I